Table 1 Baseline Characteristics
Pre NLR < 3 (N = 19) | Pre NLR ≥ 3 (N = 23) | All (N = 42) | p-value | |
|---|---|---|---|---|
Median, Age – median (range) | 61 (45-85) | 61 (24-82) | 61 (24-85) | 0.859 |
Race– no. (%) | 0.339 | |||
Caucasian | 14 (74) | 16 (70) | 30 (71) | |
African-American | 5 (26) | 4 (17) | 9 (21) | |
Asian | 0 (0) | 3 (13) | 3 (7) | |
Histology– no. (%) | 0.330 | |||
Clear Cell | 17 (89) | 16 (70) | 33 (79) | |
Non-Clear cell | 2 (11) | 9 (30) | 9 (21) | |
Smoking Status– no. (%) | >0.99 | |||
No | 10 (53) | 11 (48) | 21 (50) | |
Yes | 9 (47) | 12 (52) | 21 (50) | |
Number of Prior anti-VEGF Therapies– no. (%) | 0.093 | |||
≤1 | 16 (84) | 13 (57) | 29 (69) | |
> 1 | 3 (16) | 10 (43) | 13 (31) | |
Duration of prior anti-VEGF Therapies– no. (%) | >0.99 | |||
< 6 Months | 8 (42) | 10 (43) | 18 (43) | |
≥ 6 Months | 11 (58) | 13 (57) | 24 (57) | |
NLR at Day 15– no. (%) | <0.001 | |||
< 3 | 15 (79) | 2 (9) | 17 (40) | |
≥ 3 | 4 (21) | 20 (87) | 24 (57) | |
NLR at Cycle 3– no. (%)a | 0.001 | |||
< 3 | 13 (68) | 3 (13) | 16 (38) | |
≥ 3 | 4 (21) | 16 (70) | 20 (48) | |
Types of anti-VEGF Therapies – no. (%) | ||||
Pazopanib | 10 (34) | 10 (77) | 20 (48) | 0.019 |
Sunitinib | 6 (21) | 9 (69) | 15 (36) | 0.005 |
Axitinib | 0 (0) | 9 (69) | 9 (21) | <0.001 |
Sorafenib | 0 (0) | 6 (46) | 6 (14) | <0.001 |
Bevacizumab | 2 (7) | 5 (38) | 7 (17) | 0.021 |
Everolimus | 2 (7) | 5 (38) | 7 (17) | 0.021 |
IL2 | 10 (34) | 10 (77) | 20 (48) | 0.019 |
Histology – no. (%) | 0.330 | |||
Clear | 17 (89) | 16 (70) | 33 (79) | |
Clear Cell W/ Sarcamatoid Features | 0 (0) | 3 (13) | 3 (7) | |
Clear Cell W/ Papillary Features | 2 (1) | 3 (13) | 5 (12) | |
Medullary | 0 (0) | 1 (4) | 1 (2) | |
Heng Prognostic Score– no. (%) | 0.509 | |||
Low | 4 (21) | 8 (35) | 12 (29) | |
Intermediate | 10 (53) | 12 (52) | 22 (52) | |
High | 5 (26) | 3 (13) | 8 (19) | |
MSKCC Prognostic Score– no. (%) | 0.317 | |||
Low | 4 (21) | 9 (39) | 13 (31) | |
Intermediate | 15 (79) | 14 (61) | 29 (69) | |
Type of Immune Checkpoint Inhibitor Therapy– no. (%) | 0.220 | |||
Nivolumab | 19 (66) | 10 (77) | 29 (69) | |
Nivolumab plus Nexavar | 0 (0) | 1 (8) | 1 (2) | |
Nivolumab plus Votrient | 1 (3) | 2 (15) | 3 (7) | |
Nivolumab + Ipilimumab | 1 (3) | 0 (0) | 1 (2) | |
Ipilimumab | 0 (0) | 0 (0) | 0 (0) | |
Avelumab | 1 (3) | 0 (0) | 1 (2) | |
Pembrolizumab and Axitinib | 5 (17) | 0 (0) | 5 (12) | |
Atezolizumab and Avastin | 2 (7) | 0 (0) | 2 (5) |